Skip to main content
. 2017 Oct 30;114(46):E9903–E9912. doi: 10.1073/pnas.1716009114

Fig. 1.

Fig. 1.

A high throughput screen identifies FiVe1 as a selective inhibitor of FOXC2-expressing breast cancer cells. (A) Schematic representation of the high throughput screening platform used to identify compounds selectively toxic to FOXC2-HMLER cells. (B) Scatterplot of primary screening data displaying plate normalized Z scores of viability for FOXC2-HMLER cells versus control HMLER cells. Contents of red box indicate primary screening hits culled for further analysis. (C) Relative viability measurements of FOXC2 or control HMLER cells exposed to the indicated doses of doxorubicin for 72 h (n = 3, mean and SEM). (D) Structure of FiVe1. (E) Relative viability measurements of FOXC2 and control HMLER cells exposed to the indicated doses of FiVe1 for 72 h (n = 3, mean and SEM). (F) Relative viability measurements of the indicated FOXC2-expressing breast cancer cells after 72-h treatment with FiVe1 (n = 3, mean and SEM).